Sitagliptin Shows No Increased Cardiovascular Risk In Merck’s TECOS Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Based on results of the TECOS study, Merck will seek approval to include additional safety information in the labeling for Januvia and Janumet.
You may also be interested in...
Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza
Merck got a complete response letter from FDA on a cardiovascular risk-reduction claim for the DPP-4 inhibitor based on TECOS trial data. This places Januvia/Janumet behind Jardiance, which already has a CV safety label claim, and Victoza, which awaits an FDA decision on a supplemental NDA filed last October.
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
The latest drug development news and highlights from our FDA Performance Tracker.
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.